雄激素受体蛋白表达及其基因获得/缺失与前列腺癌预后的相关性

基础医学与临床 ›› 2010, Vol. 30 ›› Issue (8): 857-861.

雄激素受体蛋白表达及其基因获得/缺失与前列腺癌预后的相关性

周智恩李汉忠严维刚

中国医学科学院北京协和医院泌尿外科中国医学科学院北京协和医院泌尿外科北京协和医院泌尿科

收稿日期:2009-12-02 修回日期:2010-03-01 出版日期:2010-08-05 发布日期:2010-08-05
通讯作者: 李汉忠

The correlation of AR expression and AR gene gain/lose with tumor prognosis in prostate cancer

Zhi-en ZHOU, Han-zhong LI, Wei-gang YAN

Department of Urology, Peking Union Medical College Hospital, CAMS & PUMC Department of Urology, Peking Union Medical College Hospital, CAMS & PUMC

Received:2009-12-02 Revised:2010-03-01 Online:2010-08-05 Published:2010-08-05
Contact: Han-zhong LI,

摘要/Abstract

摘要： 目的探讨雄激素受体（AR）蛋白表达及其基因获得/缺失改变与前列腺癌患者预后的关系。方法前列腺癌患者19例，年龄58～90岁，平均72岁，治疗前PSA为(13.3～120)ng/mL，Gleason分级，其中高分化（Gleason评分﹤7分）2例，低分化（Gleason评分≥7分）17例。用免疫组化和FISH检测19例前列腺癌患者前列腺癌组织中的AR蛋白表达及其基因获得/缺失改变。结合临床资料分析其与前列腺癌预后的相关性。结果 19例中，发生AR基因获得2例，未发生AR基因获得17例，获得率为10.5%。其中2 例发生AR基因获得标本均来自存活组，6例死亡组病例中，无一例发生AR基因获得。未复发组阳性强度显著高于死亡组（P <0.05）。结论前列腺癌患者AR蛋白表达中强阳性以及在治疗前出现AR基因获得可能提示预后良好。

关键词: 前列腺癌, 预后, 雄激素受体, 基因获得/缺失

Abstract: Objective To study the clinical value of AR expression and its gene gain/lose in evaluating the prognosis of prostate cancer. Methods 19 patients were aged 58～90 years, and their PSA level before therapy were (13.3～120)ng/mL. As for gleason score, two had high differentiation (gleason score<7) and 17 had low differentiation (gleason score>=7).Using immunohistochemical and FISH method, we analyzed the expression of AR and its gene gain/lose in PC tissues from 19 samples. The correlation of AR expression and AR gene gain/lose with tumor prognosis in prostate cancer were analyzed in combination with the clinical data. Results 2 of 19 were found AR gene gain, the positive rate was 10.5%. The two positive samples were both from the survival group. However, none of the 6 samples from the death group was found AR gene gain. AR positive intensity of the unrecurent group were significantly higher than the death group(P<0.05). Conclusions Strong positive degree of AR expression in immunohistochemical test and AR gene gain occurring before therapy may be indicators for favorable prognosis in prostate cancer.

Key words: Prostate cancer, Prognosis, AR, Gene gain/lose

周智恩李汉忠严维刚. 雄激素受体蛋白表达及其基因获得/缺失与前列腺癌预后的相关性[J]. 基础医学与临床, 2010, 30(8): 857-861.

Zhi-en ZHOU; Han-zhong LI; Wei-gang YAN. The correlation of AR expression and AR gene gain/lose with tumor prognosis in prostate cancer[J]. Basic & Clinical Medicine, 2010, 30(8): 857-861.

[1]	刘琦郭毅郭金竹窦万臣. 颞叶海绵状血管瘤继发癫痫的手术治疗[J]. 基础医学与临床, 2019, 39(7): 1040-1044.
[2]	顾晨文刘现立. LSD1在人直肠腺癌组织中高表达[J]. 基础医学与临床, 2019, 39(1): 7-10.
[3]	沈晶沈捷胡克连欣张福泉. 37例肺大细胞神经内分泌癌的临床分析[J]. 基础医学与临床, 2018, 38(9): 1319-1322.
[4]	张潇怡王晓月. 基于癌基因组图谱挖掘胃癌预后相关基因[J]. 基础医学与临床, 2017, 37(7): 1042-1046.
[5]	王永学金滢李艳潘凌亚. 年轻早期子宫内膜癌患者保留卵巢的安全性及预后[J]. 基础医学与临床, 2017, 37(4): 443-447.
[6]	宋晓金滢李艳单莹王永学尹婕曾靖韩甜甜潘凌亚. 子宫内膜癌腹水细胞学阳性的危险因素和预后意义[J]. 基础医学与临床, 2017, 37(4): 448-453.
[7]	曾靖李艳金滢单莹王永学尹婕韩甜甜宋晓潘凌亚. 子宫内膜癌淋巴结转移的危险因素及预后分析[J]. 基础医学与临床, 2017, 37(4): 454-462.
[8]	佐晶安菊生宋艳李卓张蓉李斌吴令英. 子宫内膜癌淋巴结转移及临床病理因素与预后的相关性[J]. 基础医学与临床, 2016, 36(6): 840-845.
[9]	罗枫伍世钢刘坤平. 结直肠癌stat3表达与细胞增殖、凋亡及预后的关系[J]. 基础医学与临床, 2016, 36(11): 1531-1536.
[10]	熊焱强刘朝奇李志英. miRNA在宫颈癌早期诊断及预后中的研究进展[J]. 基础医学与临床, 2015, 35(6): 842-845.
[11]	陈罡叶文玲秦岩陈丽萌苏颖于阳高瑞通陶建瓴袁群生李航李明喜李学旺李雪梅. 代偿性酸中毒、炎性反应和病因是影响急性肾损伤预后的重要因素[J]. 基础医学与临床, 2015, 35(5): 648-653.
[12]	魏华王明刘瑞敏张天马瑾马远方齐义军. 食管鳞癌中14-3-3σ表达的临床意义及与预后的相关性[J]. 基础医学与临床, 2014, 34(8): 1044-1048.
[13]	裴丽坚阮侠黄宇光罗爱伦郭文娟王蕾王科研张玉石李汉忠. 嗜铬细胞瘤10年307例围手术期麻醉临床分析[J]. 基础医学与临床, 2014, 34(5): 695-698.
[14]	孙昭赵林周娜高鹤丽马春亮韩钦. 肝癌组织中KLF17的表达及临床意义[J]. 基础医学与临床, 2014, 34(12): 1640-1644.
[15]	杨姣蒿艳蓉冯国生陈甲信邓珊庞强秦俭. COX多因素分析和ROC曲线综合评价DNA修复基因对鼻咽癌的预后价值[J]. 基础医学与临床, 2014, 34(10): 1333-1338.